サンプル依頼リスト カート
  • English
  • Korean
表紙：コロボーマ治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1352173

コロボーマ治療の世界市場-2023年～2030年

Global Coloboma Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
コロボーマ治療の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

コロボーマ治療市場近年成長を続けています。コロボーマ治療市場とは、虹彩、網膜、視神経、脈絡膜など眼球の様々な部分に影響を及ぼす眼球組織の緩みや不完全な発達を伴う眼障害であるコロボーマの診断、管理、治療介入に焦点を当てた医療分野を指します。この眼障害には永久的な治療法はありませんが、コロボーマの管理には眼鏡、コンタクトレンズ、手術、点眼薬や眼帯が使用されます。

さらに、主に新生児におけるコロボーマの有病率の増加、より良い治療のための研究活動や臨床試験の増加、患者の嗜好に応じた遠隔医療に対する需要の高まり、新しいコンタクトレンズに対する需要の増加、高度なコンタクトレンズや眼鏡などの治療オプションにおける技術的進歩が、予測期間にわたって世界のコロボーマ市場を牽引すると予想される主な要因です。

ダイナミクス

臨床試験と研究活動の増加がコロボーマ治療市場の成長を牽引

臨床試験と研究活動の活発化は、コロボーマ治療分野における治療イノベーションを強化しています。患者が利用できる治療選択肢の幅を広げることで、コロボーマ治療に焦点を当てた臨床試験が継続的に増加しています。これらの臨床試験は、手術手技から点眼薬、コンタクトレンズに至るまで、新しい介入の安全性と有効性を評価します。臨床試験の肯定的な結果は、治療強化のための革新的な承認を増加させます。コロボーマへの注目が高まるにつれ、アンメットニーズを管理するための研究努力が拡大しています。

さらに、より正確で信頼性の高い診断ツールの開発や、コロボーマ用の高度な点眼薬やコンタクトレンズのような治療上の革新につながる継続的な研究開発活動が行われています。先進的な画像技術により、コロボーマをより早く、簡単に、正確に診断することが可能になり、医療専門家は個々の患者に合わせた治療計画を立てることができます。

遠隔医療需要の増加もコロボーマ治療市場の成長を促進

コロボーマ治療の分野では遠隔医療の需要が高まっています。遠隔医療は、コロボーマを患う患者が希望に応じて専門的な医療にアクセスする方法を提供します。これは、眼科専門医やコロボーマ治療センターのない地方や貧しい地域に住む患者にとって特に価値があります。遠隔医療はまた、長い移動距離を必要としないため、患者とその家族の負担を軽減します。

また、コロボーマ患者のための遠隔医療は、タイムリーな診察と継続的なモニタリングを提供し、より良い結果をもたらします。コロボーマを患っている人は、視力が突然変化することがあり、そのような状況では眼科の専門医が必要になることがあります。遠隔医療はまた、予約料と時間を削減します。

コロボーマとその利用可能な治療法についての認識不足が市場の成長を妨げる

コロボーマとその利用可能な治療法に関する認知度は考慮すべき重要な要素ですが、病気とその治療法に関する認知度が不足しており、市場の成長を妨げています。認知度の低さにより、コロボーマの患者は早期に関連症状に気付かず、また医師の診察を受けることの重要性を理解していません。診断の遅れは、時宜を得た介入の機会を逃すことにつながり、不可逆的な視力障害や合併症を引き起こす可能性があります。

さらに、認識不足は、安全性への懸念から、臨床試験、調査研究、治療選択肢への患者、アクセス、関与、参加の減少にもつながります。患者は、利用可能な治療法に関する情報を積極的に求めようとしないため、潜在的に有益な治療法を知らないままになってしまいます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 臨床試験と研究活動の増加
      • 遠隔医療に対する需要の高まり
    • 抑制要因
      • コロボーマとその利用可能な治療法についての認識不足
    • 機会
      • 治療選択肢の技術進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 タイプ別

  • 眼瞼コロボーマ
  • 水晶体コロボーマ
  • 黄斑コロボーマ
  • 視神経コロボーマ
  • ぶどう膜コロボーマ
    • 虹彩コロボーマ
    • 脈絡網膜コロボーマ

第8章 治療法別

  • 眼鏡
  • 眼鏡
  • コンタクトレンズ
  • 手術
  • ロービジョンエイド
  • 眼帯・点眼薬

第9章 エンドユーザー別

  • 病院
  • 眼科クリニック
  • 外来手術センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Alcon Vision LLC
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Ziemer Ophthalmic Systems
  • Jawa Pharmaceuticals pvt ltd
  • Bausch & Lomb
  • Carl Zeiss AG
  • Contamac Holdings Limited
  • Hoya Corporation
  • Johnson and Johnson Pvt Ltd
  • SynergEyes Inc.
  • CooperVision

第13章 付録

目次
Product Code: PH6954

Overview

The coloboma treatment market experiencing growth in recent years. The coloboma treatment market refers to the healthcare sector focusing on the diagnosis, management, and therapeutic interventions for coloboma, an eye disorder in which tissue is loosed or incomplete development of eye tissue affecting the various parts of the eye such as the iris, retina, optic nerve or choroid. There is no permanent cure for this eye disorder, but eyeglasses, contact lenses, surgery, and eye drops or eye patch are used for the management of coloboma.

Moreover, owing to the increasing prevalence of coloboma mainly in newborns, increasing research activities and clinical trials for better treatment, rising demand for telemedicine according to patient preference, increasing demand for novel contact lenses, and technological advancements in treatment options such as advanced contact lenses and eyewear are the major factors expected to drive the global coloboma market over the forecast period.

Dynamics

Rising Clinical Trials and Research Activities Drive the Growth of the Coloboma Treatment Market

The rising clinical trials and research activities are enhancing therapeutic innovations in the field of coloboma treatment. There is a continuous rising in clinical trials focusing on coloboma treatments by expanding the range of therapeutic options available to patients. These trials evaluate the safety and efficacy of novel interventions, ranging from surgical techniques to eye drops, and contact lenses. Positive clinical trial results increase innovative approvals for enhanced treatment. As more attention is increased on coloboma, research efforts are expanding to manage the unmet needs.

Moreover, there are continuous ongoing research and development activities that are leading to the development of more accurate and reliable diagnostic tools, and therapeutic innovations like advanced eye drops, and contact lenses for coloboma. Advanced imaging technologies enable earlier, easy, and more precise diagnosis of coloboma, allowing healthcare professionals to tailor treatment plans to individual patients.

Increasing Demand for Telemedicine Also Drives the Growth of the Coloboma Treatment Market

There is a growing demand for telemedicine in the field of coloboma treatment. Telemedicine offers a way for patients suffering from coloboma to access specialized medical care according to their preferences. This is particularly valuable for patients living in rural or poor areas without ophthalmology specialists or coloboma treatment centers. Telemedicine also eliminates the need for long travel distances, reducing the burden on patients and their families.

Telemedicine for coloboma patients also offers timely consultations and continuous monitoring with better results. Individuals, who are suffering from coloboma sometimes experience sudden changes in their vision, in such situations, they may require ophthalmology specialists, so they can easily consult through the telemedicine procedure in a comfortable way. Telemedicine also reduces appointment charges and time.

A Lack of Awareness About Coloboma and its Available Treatments Will Hamper the Growth of the Market

Awareness about coloboma and its available treatments is a key factor to consider, but there is a lack of awareness about the disease and its treatments, hampering the growth of the market. With a lack of awareness, individuals with coloboma do not recognize their associated symptoms early on or understand the importance of seeking medical attention. Delayed diagnosis can lead to missed opportunities for timely interventions, potentially resulting in irreversible vision impairment or complications.

Moreover, the lack of awareness can also leads to reduced patient, access, engagement, and participation in clinical trials, research studies, and treatment options due to unsafety concerns. Patients do not be proactive in seeking out information about the available treatments, leaving them unaware of potentially beneficial interventions.

Segment Analysis

The global coloboma treatment market is segmented based on type, treatment, end-user and region.

The Contact Lenses From the Treatment Segment Accounted for Approximately 39.2% of the Coloboma Treatment Market Share

There is no specific treatment for coloboma, but contact lenses play a crucial role in the management of coloboma, particularly when it affects the iris or leads to refractive errors. Coloboma can cause irregularities in the iris, leading to sensitivity to light known as photophobia and glare, to reduce this situation, contact lenses are mostly preferred. Mainly colored contact lenses can be used to reduce the amount of light entering the eye and improve visual comfort resulting in market dominance.

The individuals suffering from coloboma-related vision impairments, contact lenses are the most widely used and widely accepted and also can be used to optimize visual acuity. Specially designed contact lenses and colored contact lenses can help to focus light onto the retina, compensating for the abnormalities caused by the coloboma.

For instance, in April 2022, Johnson & Johnson Vision, a global leader in eye health, announced the launch of BUBBLE POP, a new range of colored contact lenses designed to meet the rising trend of makeovers among India's youth. The BUBBLE POP colored lenses are also used in vision management in coloboma patients.

Geographical Penetration

North America Accounted for Approximately 39.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Well-Established Healthcare Infrastructure

North America is home for its presence of major players such as pharmaceutical companies, medical device companies, contact lenses providers, and research activities. Several key companies in the ophthalmic and vision care sectors are majorly headquartered in North America, especially in the United States and Canada. These companies contribute significantly to market growth and research initiatives.

North America is known for its advanced and well-established healthcare infrastructure including eye hospitals and ophthalmic clinics. Regions advanced healthcare infrastructure helps to improve the patient's quality of life. The region is also dominated for its high expenditure and due to this advanced healthcare infrastructure, it is well-known research and development activity. For instance, according to the National Institute of Health, a coloboma prevalence of 0.5-0.7/10,000 live births are observed in North America annually.

Competitive Landscape

The major global players in the coloboma treatment market include: Alcon Vision LLC, Ziemer Ophthalmic Systems, Jawa Pharmaceuticals Pvt ltd, Bausch & Lomb, Carl Zeiss AG, Contamac Holdings Limited, Hoya Corporation, Johnson and Johnson Pvt Ltd, SynergEyes Inc., and CooperVision among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global coloboma treatment market. During the pandemic, research activities and clinical trials related to coloboma treatment products are temporarily disrupted due to the diversion towards COVID-19 research. Routine eye care services, including coloboma check-ups, diagnosis, and treatment, were often postponed or canceled, leading to delayed access to care for many individuals with coloboma.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global coloboma treatment market, owing to the low prevalence due to the low population and the absence of key market players in this region. However, the impact of the import and export of raw materials such as contact lenses is expected to have little influence over the global coloboma treatment market growth over the forecast period.

By Type

  • Eyelid coloboma
  • Lens coloboma
  • Macular coloboma
  • Optic nerve coloboma
  • Uveal coloboma
  • Iris coloboma
  • Chorio-retinal coloboma

By Treatment

  • Eye Glasses
  • Contact Lenses
  • Surgery
  • Low Vision Aids
  • Eye Patch or Eye Drops

By End User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global coloboma treatment market segmentation based on type, treatment, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of coloboma treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global coloboma treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Clinical Trials and Research Activities
      • 4.1.1.2. Rising Demand for Telemedicine
    • 4.1.2. Restraints
      • 4.1.2.1. A Lack of Awareness About Coloboma and its Available Treatments
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological Advancements in Treatment Options
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Eyelid coloboma *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Lens coloboma
  • 7.4. Macular coloboma
  • 7.5. Optic nerve coloboma
  • 7.6. Uveal coloboma
    • 7.6.1. Iris coloboma
    • 7.6.2. Chorio-retinal coloboma

8. By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Eye Glasses *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Eye Glasses
  • 8.4. Contact Lenses
  • 8.5. Surgery
  • 8.6. Low Vision Aids
  • 8.7. Eye Patch or Eye Drops

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ophthalmic Clinics
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Alcon Vision LLC *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Ziemer Ophthalmic Systems
  • 12.3. Jawa Pharmaceuticals pvt ltd
  • 12.4. Bausch & Lomb
  • 12.5. Carl Zeiss AG
  • 12.6. Contamac Holdings Limited
  • 12.7. Hoya Corporation
  • 12.8. Johnson and Johnson Pvt Ltd
  • 12.9. SynergEyes Inc.
  • 12.10. CooperVision

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us